SUCCESSFUL RETREATMENT WITH TAXOL AFTER MAJOR HYPERSENSITIVITY REACTIONS

被引:103
作者
PEEREBOOM, DM
DONEHOWER, RC
EISENHAUER, EA
MCGUIRE, WP
ONETTO, N
HUBBARD, JL
PICCART, M
GIANNI, L
ROWINSKY, EK
机构
[1] JOHNS HOPKINS ONCOL CTR,DIV PHARMACOL & EXPTL THERAPEUT,600 N WOLFE ST,BALTIMORE,MD 21287
[2] BRISTOL MYERS SQUIBB CO,WALLINGFORD,CT
[3] QUEENS UNIV,NATL CANC INST CANADA,CLIN TRIALS PROGRAM,KINGSTON K7L 3N6,ONTARIO,CANADA
[4] UNIV ALABAMA,DIV GYNECOL ONCOL,BIRMINGHAM,AL 35294
[5] IST NAZL TUMORI,I-20133 MILAN,ITALY
[6] INST JULES BORDET,B-1000 BRUSSELS,BELGIUM
关键词
D O I
10.1200/JCO.1993.11.5.885
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To describe the successful re-treatment of eight patients who had major hypersensitivity reactions (HSRs) to taxol and to suggest a regimen for re-treating patients who develop major HSRs. Patients and Methods: The treatment courses of eight patients who developed major HSRs and were rechallenged with taxol were reviewed. Patients in this report represent all patients who are known to have been rechallenged with taxol after major HSRs. Results: The most common approach used to rechallenge patients consisted of premeditation with multiple high doses of corticosteroids and H1- and H2-histamine antagonists followed by the initiation of the taxol infusion at a reduced rate. All patients who experienced major HSRs were rechallenged successfully. After the rechallenge, these patients received 32 additional courses of taxol without HSRs. Conclusion: Re-treatment with taxol after major HSRs is feasible using multiple high doses of corticosteroids and antihistamine premedications and a reduced taxol infusion rate under close supervision. This approach may represent a valid alternative to the termination of taxol; however, a prospective evaluation is required to determine the true efficacy of this approach.
引用
收藏
页码:885 / 890
页数:6
相关论文
共 29 条
  • [1] CONTRAST MEDIA AS HISTAMINE LIBERATORS .2. HISTAMINE RELEASE INTO VENOUS PLASMA DURING INTRAVENOUS UROGRAPHY IN MAN
    BRASCH, RC
    ROCKOFF, SD
    KUHN, C
    CHRAPLYVY, M
    [J]. INVESTIGATIVE RADIOLOGY, 1970, 5 (06) : 510 - +
  • [2] CHANG A, 1992, P AN M AM SOC CLIN, V11, P293
  • [3] DONEHOWER RC, 1987, CANCER TREAT REP, V71, P1171
  • [4] EINZIG AI, 1989, P AN M AM SOC CLIN, V8, P158
  • [5] FORASTIERE A, 1992, 2ND NAT CANC I WORKS
  • [6] PROPHYLAXIS AGAINST REPEATED RADIOCONTRAST MEDIA REACTIONS IN 857 CASES - ADVERSE EXPERIENCE WITH CIMETIDINE AND SAFETY OF BETA-ADRENERGIC ANTAGONISTS
    GREENBERGER, PA
    PATTERSON, R
    TAPIO, CM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (12) : 2197 - 2200
  • [7] PRETREATMENT HIGH-RISK PATIENTS REQUIRING RADIOGRAPHIC CONTRAST-MEDIA STUDIES
    GREENBERGER, PA
    PATTERSON, R
    SIMON, R
    LIEBERMAN, P
    WALLACE, W
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1981, 67 (03) : 185 - 187
  • [8] GREM JL, 1990, INVEST NEW DRUG, V8, P211
  • [9] PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER
    HOLMES, FA
    WALTERS, RS
    THERIAULT, RL
    FORMAN, AD
    NEWTON, LK
    RABER, MN
    BUZDAR, AU
    FRYE, DK
    HORTOBAGYI, GN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) : 1797 - 1805
  • [10] Lassus M, 1985, P AN M AM SOC CLIN, V4, P268